MiMedx Group’s (MDXG) “Overweight” Rating Reiterated at Cantor Fitzgerald

by · The Markets Daily

Cantor Fitzgerald reissued their overweight rating on shares of MiMedx Group (NASDAQ:MDXG – Free Report) in a report issued on Monday morning, Marketbeat Ratings reports. Cantor Fitzgerald currently has a $8.00 price target on the stock.

Several other analysts have also weighed in on MDXG. Wall Street Zen lowered MiMedx Group from a “hold” rating to a “sell” rating in a report on Saturday, August 1st. Citizens Jmp cut their price target on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of MiMedx Group in a research report on Thursday, August 13th. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $8.43.

Get Our Latest Stock Analysis on MDXG

MiMedx Group Stock Performance

MDXG opened at $4.45 on Monday. The stock has a market cap of $648.63 million, a P/E ratio of 111.28 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The stock’s 50 day simple moving average is $4.08 and its 200 day simple moving average is $4.12. MiMedx Group has a 1-year low of $3.03 and a 1-year high of $7.97.

MiMedx Group (NASDAQ:MDXG – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The firm had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%. As a group, equities analysts anticipate that MiMedx Group will post -0.1 EPS for the current fiscal year.

Institutional Investors Weigh In On MiMedx Group

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. acquired a new position in shares of MiMedx Group in the second quarter worth $46,795,000. Nantahala Capital Management LLC acquired a new stake in shares of MiMedx Group during the second quarter valued at $18,355,075,000. Paradigm Capital Management Inc. NY acquired a new stake in shares of MiMedx Group during the second quarter valued at $15,681,000. Punch & Associates Investment Management Inc. purchased a new stake in MiMedx Group during the 2nd quarter worth about $7,924,000. Finally, Cannell Capital LLC purchased a new stake in MiMedx Group during the 2nd quarter worth about $7,201,179,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Company Profile

(Get Free Report)

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.

Read More